Healthcare Industry News: OncoSec Medical
News Release - December 5, 2017
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific OfficerSAN DIEGO, Dec. 5, 2017 -- (Healthcare Sales & Marketing Network) -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer. Dr. Twitty joined OncoSec in 2016 as Executive Director of Clinical Science. He will join the executive leadership team and report to Daniel J. O'Connor, OncoSec's Chief Executive Officer. Dr. Twitty brings over 20 years of experience in tumor immunology and cancer immunotherapy, including the discovery and development of OncoSec's leading clinical immune monitoring and biomarker program.
"Dr. Twitty's demonstrated leadership and expertise have already made him an integral part of our management team," said Daniel J. O'Connor, Chief Executive Officer of OncoSec. "His deep experience in translational immunology and immune monitoring will continue to drive our ImmunoPulseŽ IL-12 melanoma program forward and guide the prioritization of our novel technology and product portfolio, which we believe will address significant unmet medical needs in oncology."
Dr. Twitty earned his PhD from Oregon Health & Science University where his work was focused on novel tumor vaccine strategies and was awarded an American Cancer Society fellowship training grant for his post-doctoral studies in Dr. Bernard Fox's Molecular Tumor Immunology Laboratory. After developing a preclinical and clinical immunological program focused on glioblastoma at Tocagen, Dr. Twitty joined Oncosec. Previously, Dr. Twitty held scientific positions of increasing responsibility at Bayer Pharmaceuticals and Cell Genesys, Inc.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulseŽ, for the treatment of cancer. ImmunoPulse is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or "tavo"). In Phase 1 and 2 clinical trials, ImmunoPulseŽ IL-12 has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies. In addition to tavo, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform. For more information, please visit www.oncosec.com.
Source: OncoSec Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.